The Ontario Institute for Cancer Research has agreed to work with Johnson & Johnson unit Janssen on clinical trials that aim to develop new biomarkers for detecting hormone-resistant prostate cancer and predicting therapeutic response. The project will leverage OICR's background in molecular imaging, genomics and circulating tumor cells. As part of the project, researchers will test new imaging agents in tumor evaluation and treatment response assessment.

Related Summaries